Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$236.22 +6.92 (+3.02%)

As of 08/21/2026 04:00 PM Eastern

Compare

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
5

Buy
19

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 15 have given a buy rating, and 4 have given a strong buy rating for ALNY.

Consensus Price Target

$386.62
63.67% Upside

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $386.62. The highest price target for ALNY is $566.00, while the lowest price target for ALNY is $256.00. The average price target represents a forecasted upside of 63.67% from the current price of $236.22.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

Type	Current Forecast 8/22/25 to 8/22/26	1 Month Ago 7/23/25 to 7/23/26	3 Months Ago 5/24/25 to 5/24/26	1 Year Ago 8/22/24 to 8/22/25
Strong Buy	4 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	22 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$386.62	$452.13	$463.13	$405.33
Forecasted Upside	63.67% Upside	68.24% Upside	55.70% Upside	-10.79% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Healthcare Companies	Broader Market
Consensus Rating Score	2.96	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	63.67% Upside	833.52% Upside	12.34% Upside
News Sentiment Rating	Positive News See Recent ALNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/19/2026	BMO Capital Markets 3 of 5 stars	David Lebowitz Not Rated	Initiated Coverage	Outperform	$318.00	+39.10%
8/14/2026	Wells Fargo & Company 3 of 5 stars	Derek Archila 5 of 5 stars	Lower Target	Equal Weight	$316.00 ➝ $256.00	+14.69%
8/4/2026	Truist Financial 3 of 5 stars	Danielle Brill 5 of 5 stars	Lower Target	Buy	$410.00 ➝ $315.00	+45.81%
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Joseph Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$380.00 ➝ $340.00	+57.03%
8/3/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$420.00	+104.36%
8/3/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$527.00 ➝ $450.00	+118.96%
7/31/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
7/31/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick R. Trucchio Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$485.00 ➝ $455.00	+121.43%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$445.00 ➝ $350.00	+72.34%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$400.00 ➝ $375.00	+84.65%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ulz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$400.00 ➝ $300.00	+48.01%
7/31/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$500.00 ➝ $350.00	+72.59%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$444.00 ➝ $318.00	+56.37%
7/31/2026	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$425.00	+106.83%
7/30/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$510.00 ➝ $357.00	+76.83%
7/29/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/14/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$460.00 ➝ $410.00	+46.17%
3/16/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Maury Raycroft Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$522.00 ➝ $330.00	+5.29%
2/17/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/17/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$415.00 ➝ $429.00	+36.62%
12/15/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$370.00 ➝ $351.00	-10.26%
10/31/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$449.00 ➝ $489.00	+8.21%
9/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$504.00 ➝ $566.00	+22.67%
9/11/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$280.00 ➝ $515.05	+9.93%
8/4/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/1/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$342.00 ➝ $450.00	+12.00%
8/1/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$403.00 ➝ $550.00	+38.02%
3/31/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$353.00	+31.49%
3/21/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$282.00 ➝ $371.00	+25.37%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$220.00 ➝ $220.00	-21.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:25 AM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 17, 2026. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

The current stock price is around $286, which is significantly lower than its 12-month high of $495.55, potentially offering a buying opportunity for investors looking for value.
Alnylam Pharmaceuticals, Inc. has a strong market capitalization of approximately $29.48 billion, indicating a solid position in the biopharmaceutical sector.
The company has received multiple "buy" ratings from analysts, with an average target price of around $402.67, suggesting potential upside for investors.
With a current ratio of over 3, the company demonstrates strong liquidity, meaning it can easily cover its short-term obligations, which is a positive sign for financial health.
Alnylam Pharmaceuticals, Inc. is at the forefront of RNA interference therapeutics, a cutting-edge area in medicine, which could lead to significant advancements and revenue growth in the future.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The stock has experienced volatility, with a 12-month low of $197.81, indicating potential risks associated with price fluctuations.
Despite a strong market cap, the company has a relatively high price-to-earnings ratio of around 40.95, which may suggest that the stock is overvalued compared to its earnings.
Insider selling activity has been noted, with a director selling a significant number of shares, which could raise concerns about the company's future prospects.
Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.94, indicating that the company has a considerable amount of debt relative to its equity, which could pose risks in a rising interest rate environment.
Recent price target reductions by analysts may indicate a lack of confidence in the company's short-term performance, which could deter potential investors.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $386.62, with a high forecast of $566.00 and a low forecast of $256.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 5 hold ratings, 15 buy ratings and 4 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 63.67% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 4 upgrades by analysts.

Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Chardan Capital, Citigroup, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Alnylam Pharmaceuticals more than other "healthcare" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

This page (NASDAQ:ALNY) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case

ALNY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals Bull Case

Alnylam Pharmaceuticals Bear Case

ALNY Forecast - Frequently Asked Questions

What is Alnylam Pharmaceuticals' forecast for 2026?

Should I buy or sell Alnylam Pharmaceuticals stock right now?

Does Alnylam Pharmaceuticals's stock price have much upside?

Has Alnylam Pharmaceuticals been upgraded by Wall Street analysts recently?

What analysts cover Alnylam Pharmaceuticals?

Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case